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The majority of drugs prescribed have not been tested in children and safety and efficacy of children’s medicines
are frequently supported by low quality of evidence. Therefore, a large percentage of prescriptions for children in
the clinical daily practice are used off label. Despite the several recent legislation and regulatory efforts performed
worldwide, they have not been successful in increasing availability of medicines adapted to children. Moreover, if
we consider that 30% of the prescribed drugs for children are for the respiratory field and only 4% of new
investigation projects for children research were proposed to access drugs for respiratory and allergy treatment,
there is a clear imbalance of the children needs in this therapeutic area. This narrative review aimed to describe
and discuss the off-label use of medicines in the treatment and control of respiratory and allergic diseases in
children. It was recognized that a large percentage of prescriptions performed for allergy treatment in daily clinical
practice are off label. The clinicians struggle on a daily basis with the responsibility to balance risk-benefits of an
off-label prescription while involving the patients and their families in this decision. It is crucial to increase
awareness of this reality not only for the clinician, but also to the global organizations and competent authorities.
New measures for surveillance of off-label use should be established, namely through population databases
implementation. There is a need for new proposal to correct the inconsistency between the priorities for pediatric
drug research, frequently dependent on commercial motivations, in order to comply to the true needs of the
children, especially on the respiratory and allergy fields.
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The majority of drugs prescribed have not been tested in
children and safety and efficacy of children’s medicines
are frequently supported by low quality of evidence [1].
In Europe the percentage of authorized medicines for
children is 33.3% [2]. This is explained by the lack of
clinical research in this population, caused by ethical,
scientific and technical issues, but also commercial pri-
orities [3,4]. Therefore, most of the therapies prescribed
to children are on an off-label or unlicensed basis [1].
Global legislation and regulatory efforts have been
done to overpass these limitations aiming to produce
proper research in the pediatric population, promoted* Correspondence: disolha@gmail.com
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guidelines for clinical investigation of medicinal products
in the pediatric population [5]. Since 1997, the Food and
Drug Administration (FDA) in the United States of
America (US) produced several regulation/legislation
initiatives (Pediatric Rule Regulation, 1998; Best Pharma-
ceutical for Children Act, 2002 and Pediatric Research
Equity Act, 2003) [6,7]. In Europe (EU), followed by US
experiences, new regulations were implemented since
January 2007 [8]. In both continents the measures taken
enclosed financial incentives to the industry, the addition
of 6 months extra patent protection and an additional
2 years market exclusivity for orphan medicines [1,3].
Furthermore, World Health Organization (WHO) adopted
in 2007 the WHA60.20 Resolution “Better Medicines for
Children” to undertake activities in the interest of impro-
ving pediatric medicines research, regulation and rational
[4]. One of the most important was the establishment ofd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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in its 4th version [9]. However, major discrepancies be-
tween drug prescription patterns in children and the
drugs granted pediatric exclusivity still exists. Looking
back to the last 5 years of the Pediatric Regulation from
the European Medical Agency (EMA) [Regulation(EC)
Nº1901/2006], 600 pediatric investigation plans (PIP)
were performed, of those 453 referred to not yet autho-
rized drugs, while the remaining related to new indica-
tions. However, no specific therapeutic area was addressed
more than the other, and as far as pneumology and aller-
gology are considered, they only accounted for 4% of PIP
[10]. At the same time, 30% of the prescribed drugs for
children are for the respiratory system. This suggests that
pediatric studies still do not address the real need in
pediatric drug development despite an overall increase of
medicines now available for children. Most of the drugs
available on the market, specially those considered for the
treatment of allergic diseases, are still not specifically
tested in children, particularly in the younger ones. The
aim of this review is to describe and discuss the current
off-label use of medicines in the treatment and control of
allergic diseases in children.
Review
Definitions and concepts
For approval of a new medicine, the manufacturer is re-
quired to provide the relevant national medicines regula-
tory authority specific information about its quality,
safety and efficacy. When successful, the new medicine/
formulation is approved and a Marketing Authorization
is issued along with the Summaries of Product Charac-
teristics (SPC) [11]. However, the use of drugs outside
their authorized SPC is not the concern of the author-
ities and is the sole responsibility of the prescriber [12].
Off-label use (unlabelled or unapproved) refers to pre-
scription and/or administration of a drug outside the
terms of the marketing authorization, in a way not de-
tailed in the SPC. An unlicensed (unregistered) use is de-
scribed as a formulation or dosage that has not been
approved in the country in which it is prescribed or ad-
ministered [11,13,14]. However, in the literature, the exact
definition varied between authors through time. In a re-
cent systematic review, different off-label types of use were
found, some considered dose, frequency and route of ad-
ministration, while others only contra-indications or age
range [11]. In an effort to produce a common definition
for future research and regulatory purposes, Neubert et al.
through a systematic review of the literature and a Delphi
survey with 34 experts from different areas, provided
common definitions for off-label drug use in children [14].
“Pediatric off-label use” included all pediatric uses of a
marketed drug not detailed in the SPC, namely: thera-
peutic indication; therapeutic indication for use in subsets(like age groups); appropriate strength (dosage by age);
pharmaceutical form and route of administration [14]. For
the purposes of this review this off-label definition was
considered.
Trends of off-label prescription in children
To ascertain the trends of off-label use in children, es-
pecially in respiratory and allergic diseases, a systematic
search of the literature was performed in Pubmed-
Medline in July 2013 using the terms associations, “(off-
label OR unlicensed OR unapproved OR unregistered)”
AND “children”. The studies approaching the general
prevalence of off-label use that reported allergic and/or
respiratory diseases data are described in Table 1. The
percentage of off-label use varied widely between stud-
ies, ranging from 3 to 51% of prescriptions, and reach-
ing a prevalence of 78%, when considering patients that
received at least one off-label medicine. This variability
can be explained by the different settings (countries),
age range and population sample (outpatient, inpatient,
population databases from pharmacies or from medical
prescription records). Sturkenbbom et al., compared three
different countries prescription patterns (Italy, United
Kingdom and Netherland) that, despite being quite simi-
lar, off-label prescriptions percentages differed, which
could be explained by different pediatric authorization sta-
tus of the drugs in these countries [15]. A systematic re-
view assessing off-label prescription in children found it to
be common in all settings, but higher rates were seen for
neonatal versus pediatric wards and for hospital versus
community settings [16]. Therefore, off-label prescription
should be assessed carefully and adapted to each reality
and population.
Frequency of drug prescription increases with age;
however the number of off-label medicines use de-
creases. The highest proportion of off-label prescription
in children occurs in the first two years of life
[18,20,22,24-26,29,31,34-36]. In an outpatient setting in
the US, the adjusted probability of receiving at least one
off-label prescription in a medical visit was 59% in chil-
dren’s aged 6 to 12 years, increasing to 65% from 2 to 6
year of age, to 67% if they had 1 to 2 years of age and
74% if less than 1 year (p < 0.001) [26]. Furthermore,
probability could increase by 26 to 39% if they received
more than one drug (p < 0.001) [26]. Nevertheless, this is
not consistent in all studies. In a recent outpatient popu-
lation based sample analysis in Germany there was a
predominance of off-label medication use from 3 to 13
years of age [17]. The main reason for this difference
can be related with the study population, mainly com-
posed by healthy children. When considering children
that resort to health care versus those that are hospital-
ized results differ. In a study addressing children admit-
ted to different pediatric wards the odds of being
Table 1 Summary of the studies reporting off-label medicines use and specifying respiratory off-label use
Off-label%
Reference Country Setting Study design* Age No
pa ts
No
Prescriptions
Off-label type Total Resp.
Knopf, 2013 [17] Germany Population based sample (KiGGS) Prospective; drug-use assessed by survey 0 to 17 years 889 12667 Age, dose,
indication
30 37
Morais-Almeida, 2013 [12] Portugal Allergy outpatient clinic Retrospective; clinical files analysis in 2012 0 to 6 years 500 1224 Age, dose,
indication
35 77
Ribeiro, 2013 [18] Portugal ED; University Hospital Retrospective; random sample of children
attending to the ER for 9 months in 2010
0 to 17 years 700 724 Age, dose,
indication,
route
32 28
Ballard, 2012 [19] Australia Pediatric general ward, acute-care
university Hospital
Retrospective; two groups of 150
consecutive pediatric patients admitted in
July 2009 and Jan. 2010
1 day to 11 years 300 887 Age, dose,
indication,
route
32 11
Kimland, 2012 [20] Sweden 34 Pediatric; 7 non-Pediatric
Hospitals
Prospective; data collection of all
prescriptions, in two separate 48 hour
periods (May and October 2008)
0 to 18 years 294 11 294 Age, dose,
indication,
route
34 11
Palcevski, 2012 [21] Croatia Pediatric Ward; University Hospital Prospective; clinical files analysis on a
pre-determined day of each month during
12 months (May 2010 to April 2011)
0 to 19 years 531 1643 Age,
indication,
route
13.3 5.1
Olsson, 2011 [22] Sweden Population based sample (Swedish
Prescribed Drug Register)
Retrospective; analysis of all outpatient
prescriptions performed in 2007
0 to 18 years – 2.19 million Age, dose,
indication
13.5 3.1
Phan, 2010 [23] US ED of a tertiary-care children’s
Hospital
Retrospective; all medical records
admissions analysis from January to May
2007
0 to 18 years 219 6675 Age, dose,
Indication,
route
25.6 31.8
Morales-Carpi, 2010 [24] Spain Outpatient prescriptions Prospective; analysis of all prescriptions
performed prior to the ED visit collected
from June2005 to August 2006
(14 months)
0 to 14 years 336 667 Indication,
dose,
frequency and
route
50.7 31.4
Join outpatient prescriptions to ER
random sample; University Hospital
MuhlBauer 2009 [25] Germany German statutory health insurance
provider
Retrospective; analysis of all prescriptions
performed during 2002
0 to 16 years – 1.5 million Age, indication 3.2 7
Bazzano, 2009 [26] US National Ambulatory Medical Care
Surveys (NAMCS)
Retrospective; representative sample of
outpatient visits from 2001 to 2004
0 to 18 years 312
mi
484 million Age, indication 62# 70#
Jain, 2008 [27] India Tertiary care central Hospital Prospective study, prescription survey
applied to a consecutive sample of
children admitted to the ward from May
to July 2006
1 month to
12 years
600 2064 Age, dose,
frequency,
indication
51 53
Hsien, 2008 [28] Germany Pediatric ward in tertiary care
Hospital
Prospective study of all patient files
between January and June 2006
0 to 18 years 417 1812 Age, dose,
indication
31 30
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Table 1 Summary of the studies reporting off-label medicines use and specifying respiratory off-label use (Continued)
Shah, 2007 [29] US 31 tertiary care pediatric hospitals
(PHIS database)
Retrospective study of all children
discharged from the Hospital during 2004
0 to 17 years 355409 — Age, indication 78.7# 11.2#
Ufer, 2004 [30] Sweden Population based sample (Statistics
Sweden and the National Corporation
of Swedish Pharmacists)
Retrospective study of all drug register
present in the database in 2000
0 to 15 years – 2,8million Age, dose,
indication,
formulation,
route
20.7 8.6
Schirm, 2003 [31] Netherland Pharmacies dispensing records in
northern Netherland (Interaction
database)
Retrospective study of all drugs dispensing
records in the Interaction database in 2000
0-16 years 18493 66222 Age 20.6 15.1
Pandolfini, 2002 [32] Italy Nine general pediatric hospitals
wards
Prospective; analysis of all prescriptions
performed to children in 12 week period
1 month to 14
years
1461 4255 Dose, route,
indication and
duration
60 33
McIntyre, 2000 [33] England Suburban general practice clinic Retrospective; study of all prescriptions
performed in 1998
0 to 12 years 1175 3347 Age, dose,
route
10.5 28
*All studies had a cross-sectional study design; ED- Pediatric Emergency department; #- off-label percentages is reported to visits or patients that received at least 1 off-label-drug; KiGGS- German Health Interview and
Examination Survey for Children and Adolescents; PHIS- Pediatric Health Information System.
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http://www.waojournal.org/content/7/1/4prescribed an off label drug almost doubled in children
with less than 1 year of age (OR 1.80; 95% CI 1.03–3.59,
adjusted to age, gender, number of medications prescribed
and type of ward) [37]. At the same time, several other
factors besides age interfere with the use of off label medi-
cines. The other most commonly encountered reason for
off-label prescribing was dosage, that both includes under-
dosing and over-dosing [16,17,19,20,27,30,33,35,38,39].
This is expected due to the frequent dose adjustments
needed to be performed in children. Other frequently re-
ported reasons were unapproved therapeutic indication
[18,22], followed by inappropriate age [17-19,24,38], fre-
quency of drug use and, as less frequently reported, route
of administration [19,32] and type of formulation [21].
The total absence of pediatric information in the SPC is
also a common problem in off label prevalence studies. In-
consistent information between SPC was noted, namely
for drugs with the same active compound but from diffe-
rent companies [20,40].
Drug related problems and off-label drug use in children
Off-label prescribing is not illegal, not necessarily wrong,
and is contemplated in several pediatric guidelines, but
remarkably, no reference is made that some drugs are
being recommended in an unlicensed or off-label use
basis [41]. Indeed, quality of drug therapies is not neces-
sarily related to drug license status [16]. However this
has several clinical, ethical and safety issues and there is
no explicit guide to help clinicians assess the appropri-
ateness of off-label prescribing [21]. Often it is necessary
to use medicine in an off-label basis, but this should be
appraised according to clinical indications, therapeutic
alternatives and risk-benefit analysis, and it is required
to obtain informed consent from the patient or guardian
[12]. Repeatedly a question is posed in the literature [11]
and clinicians minds: “Is off-label use more likely to be
implicated in an Adverse Drug Reaction?”
A recent review that accessed the relationship between
off-label and unlicensed medicine use and adverse drug
reactions (ADR) in children concluded that good quality
of evidence is lacking to answer this question; different
methodologies are used and definitions of off-label and
unlicensed are not consensual between studies [11].
However, results of previous studies have indicated that
there might be an association between off-label use and
ADR risk [11]. In all ADRs reported over a decade in
Danish children, one-fifth was associated with off-label
prescriptions [42].
Evidence has been contradictory and varies widely. In
studies with prospective design, incidence of ADR in
off-label drugs ranged from 2 to 39% [11]. Santos et al.
reported that in an inpatient population, off-label drug
use was significantly associated with ADRs (relative risk
2.44; 95% CI 2.12, 2.89) [39]. In another inpatient sample,Neubert et al. reported a higher prevalence of ADR with
off-label use compared with licensed ones (6.1 versus
5.6%). On the other hand, evaluating an outpatient setting
showed a frequency of ADR 2-fold higher among licensed
medication than in off-label, though the overall frequency
of ADR was low (<1%) [23].
Respiratory diseases treatments have been reported in
several associations with adverse reactions and off-label
prescription. In a retrospective analysis of all ADR re-
ported from the Swedish Drug Information System in
2000, medications used for asthma treatment were the
most frequently associated with adverse reactions. Of
those, 31% were being used off-label [30]. In another
study regarding a pharmacovigilance prospective survey
in France, exposure to drugs of “Respiratory System” in
a multivariate analysis was associated with a decreased
risk on ADR (0.20; 95% CI 0.07, 0.60). This study also
related the off-label use of a drug due to a different indi-
cation with an increased risk of ADR, particularly in in-
fants (3.94; 95% CI 1.12, 13.84) [43]. Several factors
interfere in this unknown relationship of off-label medi-
cines and ADR, as age, type of drug, disease and previ-
ous evidence of that medication use. Any decision about
off-label prescription should weight risks and benefits
and has to be based on value judgments that must in-
volve parents or guardians in the decision [44].
Off-label prescription for asthma treatment in children
Considering the global trends of outpatient prescription
in children, allergy and asthma medicines are on the top
of the most dispensed drugs [45]. If only respiratory me-
dication is considered, asthma therapies are the most
frequently prescribed (40.7% of all prescriptions) [46].
Therefore, knowledge of the authorized drugs for asthma
is essential for adequate patient care. The most commonly
used drugs for treating asthma are presented in Table 2,
accordingly to the authorized age and maximum allowed
dose limits.
Asthma management guideline recommendations, namely
Global Initiative for Asthma (GINA) or Expert Panel Re-
port 3: Guidelines for the Diagnosis and Management of
Asthma (EPR-3) [49,50] are widely followed by physicians,
and both provide recommendations for all age groups;
however, evidence supporting recommendations for pre-
school children is limited. The mainstay treatment for
asthma are inhaled corticosteroids (ICS), but guidelines
often do not provide specific recommendations for upper
doses limits specially in children [50]. In this age group,
namely in preschool children, inhaled corticosteroids are
also the most recommended for long-term asthma treat-
ment, mainly based in the previous experience in adults
and in older children, though they advise that dose-
responses are not well studied [49-51] and indeed “chil-
dren are not a small size adult”. Asthma treatment poses
Table 2 Drugs used for treatment of asthma in children and authorizations for their use according to age, dose and
indication
Category Drug Indication Age lower limit Maximum allowed dose
Europe* USA# Europe* US#
Inhaled
corticosteroids
Budesonide
(DPI; MDI)
Asthma
prophylactic treatment
2 years 6 years 400 μg/day – 2 to 6 years 800 μg/day
800 μg/day – 6 to 18 years
Budesonide (INH) 6 months 12 months 2000 μg/day 500 μg/day
Fluticasone
(DPI; MDI)
12 months 4 years 200 μg/day – 1 to 4 years; 200 μg/day (DPI) or
176 μg/day
(MDI)– 4 to 11 years;
400 μg/day – 4 to 16 years 2000 μg/day (DPI) or
1760 μg/day (MDI)≥
12 years
2000 μg/day > 16 years
Mometasone
furoate (DPI)
12 years 4 years 800 μg/day 110 μg/day – 4 to 11
years;
880 μg/day≥ 12 years
Beclomethasone
Dipropionate
4 years 5 years 400 μg/day – 4 to 12 years; 160 μg/day – 5 to 11
years;
2000 μg/day≥ 12 years 640 μg/day≥ 12 years
Oral
anti-leukotrienes
Montelukast 6 months 6 months 4 mg/day – 6 months to
5 years;
5 mg/day – 6 to 14 years
10 mg/day ≥15 years
Short-acting
β2 agonists
Salbutamol or
Albuterol
Asthma reliever
treatment
None 4 years
(MDI)
800 μg/day <12 years (MDI) 1080 μg/day (MDI)
2 years
(INH)
10 mg/day < 12 years (INH) 5 mg/day- 2 to
12 years (INH)
20 mg/day≥ 12 years(INH) 10 mg/day≥ 12 years
(INH)
Terbutaline (DPI) 3 years — 4 mg/day – 3 to 12 years —
6 mg/day≥ 12 years
Long-acting
β2 agonists
Salmeterol Asthma
prophylactic treatment
4 years
(MDI; DPI)
4 years
(DPI)
100 μg/day
Formoterol (DPI) 6 years 5 years 24 μg/day – 5 to 12 years 24 μg/day
48 μg/day≥ 12 years
Combination
long-acting β2
agonists with
inhaled corticosteroids
Budesonide/
Formoterol (DPI)
6 years 12 years 320/18 μg/day – 6 to
12 years
640/18 μg/day
640/18 μg/day≥ 12 years
Fluticasone/
Salmeterol
4 years
(DPI)
4 years
(DPI)
200/100 μg/day
(DPI; MDI)- 4 to 11years
200/100 μg/day
(DPI)- 4 to 11years
4years
(MDI)
12 years
(MDI)
1000 μg/100day
(DPI; MDI)- ≥12 years
1000 μg/100day
(DPI)- ≥12 years
460/42 μg/day (MDI)
DPI- dry powder inhaler; MDI- Metered dose inhaler; INH- inhalation suspension *Data obtained in the Summaries of Product Characteristics (SPC) of one European
country (Portugal, Infarmed [47]), except for mometasone furoate obtained from the UK SPC #Data obtained in the FDA approved Drugs Database [48].
Comparison between an European country (regulated by EMA and the national authority) and the United States of America (regulated by FDA).
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between recurrent wheezing and asthma phenotypes oc-
curs, making diagnosis and therapeutic decisions contro-
versial [52,53]. Moreover, some therapeutic options are
not deprived of side effects [49,52].
In children, inhaler type and child’s ability to use it
correctly also interferes with the treatment. Beclometha-
sone, budesonide and fluticasone are available as either
metered dose inhaler (MDI) or dry powder inhaler
(DPI). Preschool children are not able to cooperate with
the proper inhalation technique demanded by DPI,
therefore these devices are not licensed for this popula-
tion [52]. Furthermore, some new drugs like mometa-
sone and ciclesonide are still not approved under
12 years [52].
In long-term treatment, if control is not achieved,
other treatment associations can be considered, but their
efficacy and safety are also not established in some cases.
Long acting β2 agonists (LABA) are endorsed in the
EPR-3 as one option for step-up therapy for persistent
asthma in association to inhaled corticosteroids. Though
they advise that these drugs aren’t adequately studied in
children with less than 4 years of age, they are recom-
mended as an add-on in the upper steps of the stepwise
approach [50]. On the other hand, GINA guidelines spe-
cifies asthma therapy for children under 5 years of age,
where LABA aren’t approved, indicating oral anti-
leukotriene’s as an option [54,55]. Guidelines are recom-
mendations on the appropriate management, diagnosis
and treatment, but they differ between each other and
vary widely between countries, however they do not re-
place clinician’s knowledge and skills. Several studies
assessed the pediatric use of asthma drugs in different
countries through cohort and cross-sectional studies
[46,56,57]. TEDDY study is a 6 years retrospective ana-
lysis of outpatient medical records concerning pediatric
asthma that combined databases from Netherland, Italy
and United Kingdom and described the use of asthma
drugs to be more frequent in children less than two
years of age [56] to whom drug authorizations are scarce
(Table 2). As expected, asthma treatment in children
under 2 years present the highest prevalence of off-label
use [12,46,56,57]. The most frequent drugs used off label
are the short acting β2 agonist (SABA) salbutamol, ran-
ging from 24 to 45% [56,57], and inhaled corticosteroids,
from 26 to 80% [12,56,57]. Fixed combination of ICS
and LABA were also often prescribed [56]. When con-
sidering types of off-label use, salbutamol and ICS were
the most frequently reported due to age limits (19%),
and salmeterol-fluticasone association due to inadequate
indication [33,57]. Other studies report off-label use of
these drugs due to higher than recommended doses; this
could be explained mainly owing to inconsistencies found
between the SPC and country guideline recommendations[19,35]. Many children with asthma are not managed in
accordance with the set guidelines, as they vary widely in
the literature and are not consistent with the SPC, leaving
physicians to prescribe off-label. Most recognize it and be-
lieve that off-label prescription is appropriate, however
they have efficacy and safety concerns. Moreover in a re-
cent study only one third of the physicians self-reported
that children’s guardians/parents were informed of off-
label treatment use [58].
Off-label use for rhinitis treatment in children
Allergic rhinitis is the most prevalent chronic allergic
disease in children [59]. Oral second-generation anti-
histamines and intranasal corticosteroids are considered
the first line treatments [59-61]. In Table 3 are described
some examples of the most often used drugs for allergic
rhinitis, accordingly to the age limit and maximum
allowed dose. The majority of intranasal corticosteroids
and some of the anti-histamines lack pediatric approval
and this is recognized by the guidelines [59,61]. These
drugs are recommended for children by extrapolation
from pharmacological and clinical data in adults. How-
ever, the absorption, distribution and metabolism in chil-
dren diverge from adults and age-related differences in
children exist in their ability to metabolize, absorb, ex-
crete and transform medications, therefore efficacy and
safety might be affected [59,62]. Although nasal cortico-
steroids can be associated with some side effects, includ-
ing bone mineral density loss, adrenal suppression and
growth retardation, these were only reported in one
study using beclomethasone [60,62]. Therefore, only the
lowest possible dose for symptoms control is favored
[61]. Intranasal corticosteroid use before age of 2 is con-
sidered off-label and only mometasone is authorized in
less than 4 years of age in the US (Table 3). As for anti-
histamines, accordingly to the most recent guideline up-
date, first generation drugs should not be used for rhin-
itis in children due to their side effects [63]. However,
the most frequently available anti-histamines over the
counter in the US are from first generation. This raised
public health concerns about their use in children and,
in the US, campaigns have been conducted to advise for
safety concerns and recommend against their use under
the age of two [64]. If considering an outpatient setting,
the majority of off-label prescriptions were from pediatri-
cians (54.4%), but a large number, 34.3%, were self-
medications [24]. Despite their widely use only few studies
have been performed to assess the magnitude of off-label
drug in children for rhinitis.
In a recently published study assessing off-label use in
an allergy outpatient clinic, the most frequently pre-
scribed drugs were nasal corticosteroid in 76% of all pre-
scriptions, anti-histamines were used off-label in 22%
[12]. T’Jong et al. study reported that of all respiratory
Table 3 Drugs used for treatment of allergic rhinitis, urticaria and atopic eczema in children and their authorizations
for their use according to age, dose and indication
Category Drug Indication Age lower limit Maximum allowed dose
Europe USA Europe* US#
Nasal inhaled
corticosteroids
Budesonide Allergic Rhinitis 6 years 6 years 400 μg/day 400 μg/day
Fluticasone
furoate
4 years 4 years 50 μg/day – 4 to 12 years 200 μg/day
200 μg/day≥ 12 years
Mometasone 6 years 2 years 100 μg/day 100 μg/day −2 to 11 years;
200 μg/day≥ 12 years
Oral antihistamines Cetirizine Allergic rhinitis;
Urticaria
2 years 6 months 5 mg/day – 2 to 6 years; 2.5 mg/day- 6 months to
1year
10 mg/day > 6 years 5 mg/day- >1 year to 5 years
10 mg≥ 6 years
Levocetirizine 2 years 6 months 2.5 mg/day – 2 to 6 years; 1.25 mg 6 months to 5 years
5 mg/day – older than 6 years 2.5 mg- 6 years to 11 years
5 mg ≥ 12 years
Loratadine 2 years 2 years 5 mg/day – 2 to 6 years;
10 mg/day > 6 years
Desloratadine 12 months 6 months 1.25 mg/day – 1 to 5 years; 1 mg – 6 to 11 months
2.5 mg/day – 6 to 12 years; 1.25 mg/day – 1 to 5 years;
5 mg/day≥ 12 years; 2.5 mg/day – 6 to 11 years;
5 mg/day≥ 12 years
Fexofenadine 6 years 6 years 60 mg/day – 6 to 11 years 30 mg/day- 6 months
to < 2 years
180 mg/day≥ 12 years 60 mg/day – 2 to 11 years
180 mg/day≥ 12 years
Diphenhydramine 6 years 2 years 75 mg/day – 6 to 12 years; 37.5 mg/day – 2 to 5 years
150 mg/day > 12 years 150 mg/day – 6 to 11 years
300 mg/day≥ 12 years
Topical
immunomodulators
Pimecrolimus Atopic
Dermatitis
2 years 2 years Twice daily, intermittent
treatment 12 months
Twice daily, intermittent
treatment 12 months
Tacrolimus 2 years 2 years 0.03%- 2 to 15 years 0.03% – 2 to 15 years
0.1%≥ 16 years 0.1%≥ 16 years
(twice daily for 3 weeks
then once daily, intermittent use)
(twice daily for intermittent use)
*Data obtained in the Summaries of Product Characteristics (SPC) of one European country (Portugal, Infarmed [47]) #Data obtained in the FDA approved Drugs
Database [48].
Comparison between an European country (regulated by EMA and the national authority) and the United States of America (regulated by FDA).
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lation, half of the patients were prescribed antihistamines
and nasal corticosteroids in an off-label basis [46]. In other
studies assessing systemic anti-histamines, off-label pre-
scribing ranged from 6.5% to 43% [17,23,30,33,35]. Cetiri-
zine [65,66], levocetirizine [62,67] and loratadine [68] have
been the most investigated for long term safety in pediatric
population. Despite pharmacokinetic studies have been
performed in new generation anti-histamines, long-term
safety studies in children are still lacking [69,70]. Indeed,
due to the proven efficacy of nasal corticosteroids andanti-histamines on disease control in children by reducing
disease-associated impairment and improving disease-
related quality of life, more studies are needed about
safety in order for physicians to perform a rational deci-
sion of the large number of options available in the mar-
ket [62,69,71].
Off-label medicines use for treating urticaria and atopic
eczema in children
In a joint initiative, the European Academy of Allergol-
ogy and Clinical Immunology (EAACI), the EU-funded
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European Network (GA2LEN), the European Dermatol-
ogy Forum (EDF) and the World Allergy Organization
(WAO) published a guideline for urticaria management
[72]. In it was recommended as the first line treatment
for urticaria the use of oral anti-histamines in an up-
dosing step up therapy until up to 4 times the dose.
These new recommendations were also advised for chil-
dren, adjusting the dose accordingly to the weight [72].
Recent randomized, double-blind, placebo controlled tri-
als in adults support the efficacy and safety of this up-
dosing use, namely in cold contact urticaria [73,74].
Nevertheless, due to the absence of controlled trials in
children, these changes were not updated in the SPC of
the anti-histamines in the market and as stated above
only a few of them were actually studied for their long
term effects in children. This explains why a large por-
tion of the off-label type of use when considering anti-
histamines is due to a different dose prescription [12].
For chronic disease it is also important not only efficacy
and safety, but also compliance to the treatment. Chil-
dren pediatric formulations, namely under 6 years of
age, are usually liquid and it is necessary to make them
stable, sterile, pleasant and long lasting. Furthermore as
children grow, drug doses should be adapted to weight
and, to avoid dosing errors, the means to deliver accur-
ate doses of these liquid formulations need to be avail-
able [62]. In atopic dermatitis, anti-histamines also are
considered as potential benefit to reduce pruritus, and
although no evidence exists to support their role in
treatment they can be useful in reducing this disturbing
symptom in children [69].
Accordingly to the most recently published guidelines
for atopic dermatitis the main treatment is skin hydration,
topical anti-inflammatory medications and antipruritic
therapy [75-77]. For anti-inflammatory medication, topical
glucorticosteroids or topical calcineurin inhibitors are
used. For topical corticosteroids numerous substances are
available, grouped by potency. Potent and very potent cor-
ticosteroids (Group III and IV) are more likely to cause
systemic or local side effects (like adrenal suppression,
skin atrophy or striae) than group I (mild) and II (moder-
ate strength); therefore the first should be avoided for
treatment in infants, whose higher surface area to body
weight ratio and age dependent maturation of the skin
barrier function leaves them vulnerable to over-dosing
[75,78]. According to the FDA, use of these products are
also limited by age and duration of treatment [78]. Still
and specially from birth to 4 years of age, topical cortico-
steroids were prescribed off-label in 13% of all prescrip-
tions, of those 58% due to high dosage use [35]. Recent
guidelines recommend that for mild disease activity, a
small amount of topical corticosteroids twice to thrice
weekly until reaching a mean monthly dose of 15 grams(g) in infants, 30 g in children and up to 60 to 90 g in ado-
lescents and adults [75].
Nowadays new topical anti-inflammatory alternatives
include calcineurin inhibitors and fourth generation cor-
ticosteroids. This fourth generation corticosteroids, like
methylprednisolone aceponate seem to have a favorable
benefit-risk-ratio in this age group [79]. Regarding top-
ical immunomodulators, calcineurin inhibitors, like ta-
crolimus and pimecrolimus, as they don’t cause skin
atrophy, are favored for long-term management and to
be used in delicate body areas, such as the eyelid region,
the perioral skin, genital area, the axilla or the inguinal
fold [80]. As a result of the immunosuppressant activity
of these drugs there are concerns about their potential
to promote skin infections and malignancies, particularly
lymphomas, following long-term treatment [80]. These
drugs are only approved for children with more than
2 years of age by FDA and EMA (Table 3). Due to the
high prevalence of atopic dermatitis in children, which
begins in over 60% of cases during the first year of life,
usually affects more sensitive-skin areas and have a
higher body surface/volume ratio that enhances the risk
of systemic exposure to corticosteroids, it was seen an
increase of use in topical calcineurin inhibitors [77,80].
Off-label use, particularly in infants in the US, reached a
high prevalence of prescriptions in 2004, approximately
525,000 (14% of yearly prescriptions) for pimecrolimus
and 69,000 (7%) for tacrolimus [80]. This led FDA to in-
clude a black box warning in 2005, changed to a box
warning in 2006, on the labels of topical tacrolimus and
pimecrolimus. Still, further discussion has occurred and
even with large epidemiological data, at current time,
FDA maintains that may be “a possibility of an associ-
ation” [80]. However, guidelines recommend clinicians
to use tacrolimus ointment, specially for eczema on the
face, eyelid, and skin folds that is unresponsive to low-
potency topical steroids in children older than 2 years
[75,77]. Other systemic drugs for atopic dermatitis treat-
ment also recommended off-label in children and ado-
lescents is cyclosporine, however only reserved in the
most severe and refractory to classical treatment and
usually demanding specialized care [76].
Unmet needs
According to the World Health Organization the ideal
medicine for a children is “one that suits the age, physio-
logical condition and body weight of the child taking them
and is available in a flexible solid oral dosage form that
can be taken whole, dissolved in a variety of liquids, or
sprinkled on foods, making it easier for children to take”
[81]. However this reality is far from us and still, as it was
seen, drugs are not adequately studied for children.
In order to improve drug use and safety of treatment
in children there is a need to increase research not only
Silva et al. World Allergy Organization Journal 2014, 7:4 Page 10 of 12
http://www.waojournal.org/content/7/1/4for new drugs, but also in medicines that are in market
but are not adequately adjusted for children. Several
worldwide regulatory efforts, namely those included in
the initiative “Better Medicines for Children” allowed
that a large number of new products with pediatric indi-
cations and age-appropriate pharmaceutical forms to be
now authorized and made available. Furthermore, a high
number of agreed pediatric investigation plans indicate
that further products are appearing. However, there is an
imbalance between the priorities for pediatric drug re-
search and the need of the children. This is specially vis-
ible for respiratory and allergy treatment medicines [3,10].
Furthermore, physicians frequently encounter an in-
consistency in what is proposed on the guidelines and
the drugs summary of product recommendations [35].
There is an urgent need for regulations of off-label pre-
scribing not only for medical institutions, but also for
physicians [82]. In a daily basis they are confronted with
questions of safety, apprehension of potential ADR, effi-
cacy and ethical issues. As Gazarian et al. reported most
physicians believe that off-label prescribing is adequate
and they are doing it considering that the benefits out-
weigh the risks, but due to lack of evidence, frequently
they are unaware of the true balance [13].
The overall level of unlicensed and off-label pediatric
prescribing suggests the need to perform well designed
clinical studies in children, for that pharmaceutical
industry and academic organizations should be encour-
aged [37,82]. The previously implemented Pediatric Use
Marketing Authorization (PUMA), which offered 8 years
of data protection and 10 years of market exclusivity to
any new off-patent product developed exclusively for use
in the pediatric population was not successful and in the
last 5 years only one was granted. Probably it did not
outweight the economical risks and competition with
previously implemented drugs. New measures are needed
to encourage the market in a new path. Furthermore,
more awareness should be enforced using population-
based databases to monitor off-label prescription and by
that increase awareness of the true children’s needs and
interests.
Conclusions
Off-label use in children is common and differs between
countries, inpatient and outpatient settings and age. Re-
spiratory and allergy medicines are on the top of the
most prescribed off-label drugs in children, nevertheless
this has not been accompanied with new research of
their safety and efficacy in children, specially with those
drugs already in market. In this narrative review it was
recognized that a large percentage of drugs prescription
in an allergist daily clinical practice are off-label. It is
fundamental to increase awareness of this reality, as it is
the responsibility of the clinician to balance risk-benefitsof the prescription. Parents/guardians should be informed
and involved in the decision in order to prevent misunder-
standings, increase compliance and awareness to adverse
effects in the pursuance of a good clinical outcome. There
is a need for new studies with a better design to access
long-term safety and efficacy of respiratory and allergy on-
market drugs in children, primarily in those under two
years of age. New ways should be found by the competent
authorities to promote more research accordingly to the
patients needs, namely on respiratory and allergy field.
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